Envestnet Asset Management’s Mustang Bio MBIO Stock Holding History

Envestnet Asset Management’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-27	Closed	-$9K	–	4011
2022 Q3	$9K	Sell	27 -89	-77%	-$41.2K	﹤0.01%	3885
2022 Q2	$51K	Buy	116 +35	+43%	+$19.4K	﹤0.01%	3819
2022 Q1	$61K	Buy	81 +25	+45%	+$20.5K	﹤0.01%	3846
2021 Q4	$70K	Buy	56 +32	+133%	+$51.7K	﹤0.01%	3790
2021 Q3	$48K	Buy	24 +3	+14%	+$6.44K	﹤0.01%	3638
2021 Q2	$52K	Buy	21 +5	+31%	+$12.3K	﹤0.01%	3601
2021 Q1	$40K	Buy	+16	New	+$47.6K	﹤0.01%	3457
2020 Q1	–	Sell	-13	Closed	-$41K	–	3069
2019 Q4	$41K	Hold	13	–	–	﹤0.01%	3039
2019 Q3	$33K	Hold	13	–	–	﹤0.01%	3003
2019 Q2	$37K	Hold	13	–	–	﹤0.01%	3005
2019 Q1	$34K	Hold	13	–	–	﹤0.01%	2935
2018 Q4	$29K	Hold	13	–	–	﹤0.01%	2822
2018 Q3	$60K	Buy	+13	New	+$65K	﹤0.01%	1231

Other funds holding MBIO

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Envestnet Asset Management's MBIO Position: Q4 2022 in Review

Envestnet Asset Management sold out of Mustang Bio (MBIO) in Q4 2022, closing a stake of 27 shares — an estimated $9K sold.

Envestnet Asset Management first reported a position in MBIO in Q3 2018 and held it in 13 quarters. The position peaked at $70K in Q4 2021. 60 funds tracked by Wall St. Rank hold MBIO as of Q4 2022.

Envestnet Asset Management reported no remaining Mustang Bio position as of Q4 2022 after selling out during the quarter.
Envestnet Asset Management sold 27 Mustang Bio shares in Q4 2022, an estimated $9K.
Envestnet Asset Management first reported a position in Mustang Bio in Q3 2018 and held it in 13 quarters.
Envestnet Asset Management's Mustang Bio position peaked at $70K in Q4 2021.
60 funds tracked by Wall St. Rank held Mustang Bio as of Q4 2022.

Based on Envestnet Asset Management's 13F filing for Q4 2022, filed 7 Feb 2023.